{"id":8993,"date":"2016-05-30T09:38:50","date_gmt":"2016-05-30T12:38:50","guid":{"rendered":"https:\/\/www.infobioquimica.com\/new\/?p=8993"},"modified":"2016-05-30T09:38:50","modified_gmt":"2016-05-30T12:38:50","slug":"therapeutic-anti-cd3-monoclonal-antibodies-from-bench-to-bedside","status":"publish","type":"post","link":"https:\/\/infobioquimica.com\/new\/2016\/05\/30\/therapeutic-anti-cd3-monoclonal-antibodies-from-bench-to-bedside\/","title":{"rendered":"Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside"},"content":{"rendered":"<p>Investigations over the last 20 years have shown that anti-CD3 monoclonal antibodies (mAbs) effectively treat autoimmune disease in animal models and have also shown promise in clinical trials. Tolerance induction by anti-CD3 mAbs is related to the induction of Tregs that control pathogenic autoimmune responses. Here, we review preclinical and clinical studies in which intravenous or mucosal administration of anti-CD3 mAbs has been employed and provide an outlook on future developments to enhance the efficacy of this promising therapeutic approach.<\/p>\n<p><a href=\"https:\/\/www.infobioquimica.com\/new\/wp-content\/uploads\/2016\/05\/Therapeutic-anti-CD3.pdf\" target=\"_blank\">Click here to view PDF<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Investigations over the last 20 years have shown that anti-CD3 monoclonal antibodies (mAbs) effectively treat autoimmune disease in animal models and have also shown promise in clinical trials. Tolerance induction by anti-CD3 mAbs is related to the induction of Tregs that control pathogenic autoimmune responses. Here, we review preclinical and clinical studies in which intravenous [&hellip;]<\/p>\n","protected":false},"author":2620,"featured_media":8996,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"twitterCardType":"","cardImageID":0,"cardImage":"","cardTitle":"","cardDesc":"","cardImageAlt":"","cardPlayer":"","cardPlayerWidth":0,"cardPlayerHeight":0,"cardPlayerStream":"","cardPlayerCodec":"","footnotes":""},"categories":[655],"tags":[9286,9294,9292,9290,9284,9288],"class_list":["post-8993","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticias-ingles","tag-anti-cd3-monoclonal-antibodies","tag-cd3","tag-mabs","tag-monoclonal-antibodies-mabs","tag-tolerance","tag-tolerance-induction"],"acf":[],"_links":{"self":[{"href":"https:\/\/infobioquimica.com\/new\/wp-json\/wp\/v2\/posts\/8993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/infobioquimica.com\/new\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/infobioquimica.com\/new\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/infobioquimica.com\/new\/wp-json\/wp\/v2\/users\/2620"}],"replies":[{"embeddable":true,"href":"https:\/\/infobioquimica.com\/new\/wp-json\/wp\/v2\/comments?post=8993"}],"version-history":[{"count":2,"href":"https:\/\/infobioquimica.com\/new\/wp-json\/wp\/v2\/posts\/8993\/revisions"}],"predecessor-version":[{"id":8997,"href":"https:\/\/infobioquimica.com\/new\/wp-json\/wp\/v2\/posts\/8993\/revisions\/8997"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/infobioquimica.com\/new\/wp-json\/wp\/v2\/media\/8996"}],"wp:attachment":[{"href":"https:\/\/infobioquimica.com\/new\/wp-json\/wp\/v2\/media?parent=8993"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/infobioquimica.com\/new\/wp-json\/wp\/v2\/categories?post=8993"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/infobioquimica.com\/new\/wp-json\/wp\/v2\/tags?post=8993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}